Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207129 · ClinicalTrials.gov registry record · Phase 1
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
A Phase 1 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00207129 is a Phase 1 study that has completed, run by R-Pharm. The registered enrollment target is 25 participants.
The verdict
NCT00207129, a Phase 1 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.
Interventions
- DRUG Capecitabine
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207129
The ClinicalTrials.gov registry entry for NCT00207129 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00207129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207129 about?
NCT00207129 is a clinical study titled "Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies". The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.
What is the current status of trial NCT00207129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-10. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00207129?
The interventions under investigation include: Capecitabine (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00207129?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.